Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
Jerome Bettis and Robin Miller are teaming up with Sanofi US to raise awareness of life-threatening allergic reactions (anaphylaxis) and spread the word that Auvi-Q™ (epinephrine injection, USP) is now available by prescription in pharmacies nationwide. Bettis, who is allergic to shellfish, and Miller, who is allergic to eggs, hope to help educate adults and caregivers of children at risk for severe allergic reactions.
Auvi-Q is the first-and-only epinephrine auto-injector with audio and visual cues for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. The size and shape of a credit card and the thickness of a smart phone, Auvi-Q is a breakthrough in epinephrine auto-injector design that talks patients and caregivers step-by-step through the injection process.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59439-auvi-q-epinephrine-injection-usp-now-available-by-prescription-in-u-s
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management and clinical information exchange solutions, today announced the expansion of Emdeon Clinical Exchange™, its technology-enabled solution designed to improve business and clinical outcomes and care continuity.
Emdeon Clinical Exchange encompasses products and services that are designed to unite healthcare communities. Today, hospitals, physicians, labs, payers and pharmacies use Emdeon’s leading healthcare information network to securely exchange health information over six billion times annually. These healthcare stakeholders are demanding greater connectivity to each other and the ability to facilitate comprehensive, end-to-end clinical information exchange.
To view Multimedia News Release, go to http://www.multivu.com/mnr/48120-emdeon-expands-clinical-information-exchange-capabilities
Upsher-Smith Laboratories, Inc. today announced the nationwide launch of Provella™, a unique probiotic dietary supplement specifically designed for women to promote digestive, feminine, and immune health.* Provella™ helps restore and maintain balance of good bacteria to support digestive and vaginal health.* Taken once-daily by mouth, Provella™ tablets contain a proprietary blend of six bacteria strains that include: Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus reuteri, and Bifidobacterium bifidum.
Provella™ is available without a prescription behind the pharmacy counter at retail pharmacies nationwide and online at www.drugstore.com. Consumers can also ask any local pharmacist to order Provella™ using List Number 0245-1060-30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56871-upsher-smith-provella-probiotic-supports-digestive-feminine-immune-health
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Delivering a healthy dose of good news to Midwest families, Meijer announced today that its free pre-natal vitamins prescription program has filled its 1,000,000th prescription, at a cost savings of nearly $14 million to Midwest families.
The announcement, made by Hank Meijer, Co-Chairman and CEO, came as the Midwest retailer reported that its pharmacies had hit the million-mark milestone earlier this week.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/meijer/50770/